TickerFactsScreenerDevelopers

Avalo Therapeutics, Inc. (AVTX) — Operating Cash Flow

Annual figures by fiscal year, from SEC filings.

2015: -$10.16M2016: -$14.57M2017: $12.58M2018: -$3.13M2019: -$19.13M2020: -$40.54M2021: -$70.89M2022: -$26.75M2023: -$30.68M2024: -$49.06M2025: -$51.46M-$51.46M
2015Operating Cash Flow (USD)2025
Fiscal YearOperating Cash FlowChange YoY
2025-$51.46M-4.9%
2024-$49.06M-59.9%
2023-$30.68M-14.7%
2022-$26.75M+62.3%
2021-$70.89M-74.9%
2020-$40.54M-111.9%
2019-$19.13M-511.7%
2018-$3.13M-124.9%
2017$12.58M+186.3%
2016-$14.57M-43.4%
2015-$10.16M—